Disease and Economic Burden of Prostate Cancer in Malaysia: A Review

  • Norzaher Ismail National University of Malaysia (UKM)
  • Aniza Ismail
Keywords: Prostate cancer-burden of disease-economic-cost-quality of life


AbstractIntroduction   In Malaysia prostate cancer is ranked as fifth type of cancer among male. Unlike other cancers, prostate cancer is slow growth type of cancer; hence most patients may be asymptomatic despite having the disease. The burden associated with prostate cancer disease started from the diagnosis, the progress of disease and the varying impact of the available treatment options till the quality of life.Aim                 The review focused on the disease and economic burden of prostate cancer disease towards country and patient personally.Method           A search was conducted to review related published studies on economic burden of the prostate cancer through PubMed/MEDLINE, Google Schorlar and Science Direct searching engines databases using keywords: Prostate cancer, economic burden and disease burden, treatment burden and treatment cost. For exploration on the burden itself, the keywords used were economic cost, mortality, morbidity, quality of life , treatment burden, palliative care. A review on the morbidity and mortality comparing global, Asian and Malaysia situation reviewed from previous review paper and online data.Conclusion     Economic burden of prostate cancer include quality of life, treatment cost and palliative cost and palliative support care system. Development and improvise of the treatment facilities and equipment, strong knowledge and clinical training of staff in the treatment of cancer should be well planned in order to reduce the increasing burden of prostate cancer in Malaysia.


WHO. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence

worldwide in 2012 [Internet] Lyon: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr.

Parkin DM, Muir CS, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents, volume VI. Lyon: International Agency for Research on Cancer Scientific Publications; 1992.

Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene.2014;2:596-605.

Malaysian National Cancer Registry Report (MNCR) 2007-2011

Lim GCC, Rampal S, Halimah Y (Eds). Cancer Incidence in Peninsular Malaysia, 2003-2005. National Cancer Registry. Kuala Lumpur.2008

Zainal-Arifin O, Nor-Saleha IT (2011). Natrional Cancer Registry.Malaysia Cancer Statistics – Data and Figure 2007. Putrajaya: National Cancer Registry. Ministry of Health, Malaysia

Gerard CCL (2003). Cancer in Malaysia -there is light at the end of the tunnel. Med J Malaysia, 58, 632-5.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin 2013;63:11-30.

Ganz PA. Survivorship: adult cancer survivors. Prim Care. 2009;36:721-741.

Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-383.

Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118:5955-5963.

Chamie K, Connor SE, Maliski SL, Fink A, Kwan L, Litwin MS. Prostate cancer survivorship: lessons from caring for the uninsured. UrolOncol. 2012;30:102-108.

Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland CS. Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer. 2011;117:2779-2790.

Ramsey SD, Zeliadt SB, Hall IJ, Ekwueme DU, Penson DF. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. J Urol. 2007;177:1992-1999.

He JCW. Chinese cancer registry annual report 2012. Beijing: China Military Medical Science Press; 2013.

Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 2014;46:109-23.

Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92.

Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer

Schersten T, Baile Ma, Asua J et al. Prostate cancer screening. Evidence synthesis and update.Statement of Finding.(INAHTA Joint Project). Vitoria-Gasteiz: Dpt. of Health Basque Government. Basque Office for Health Technology Assessment, Osteba.1999

Mohd Aminuddin MY.Mass screening for prostate diseases. Technology Review Report 022/07. Health Technology Assessment Unit, Medical Development Division, Ministry of Health.2007

Cancer Facts and Figures 2008.

Dawan D. , Rafindadi A.H , Kalayi G.D ,Benign Prostate Hyperplasia and Prostate Carcinoma in Native African, British Journal of Urology International , 85:9 ,pp 1074-1075 , June 2000.

National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology™.Prostate cancer, v3.2012.NCCN. www.nccn.org.

Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010–2020. J. Natl Cancer Inst. 103, 117–128 (2011).

Stokes ME, Ishak J, Proskorovsky I et al. Lifetime economic burden of prostate cancer. BMC Health Serv. Res. 11, 349–354 (2011).

Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 2007;109:518-27

Hooi LN, Devaraj T. A hospital based study of cancer admissions. Med J Malaysia 1998;53: 22 –9.

Sharifa Wan P.E , Syed Mohamed A.S, Noraziani Khamis et al.Skeletal-Related Event Event among Breast and Prostate Cancer Patients:Towards New Treatment Initiation in Malaysia`s Hospital Setting. Asian Pacific J Cancer Prev, 14 (5), 3357-3362

Bernard DS,FarrSL,Fang Z(2011).National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J ClinOncol, 29, 2821-6.

Konski A (2004). Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis for prostate cancer. Int J RadiatOncolBiol Phys, 60, 1373-8.

Bagi CM (2005). Targeting of therapeutic agents to bone to treat metastatic cancer.Advanced Drug Delivery Reviews, 57, 995-1010.

Penson DF, Moul JW, Evans CP, et al (2004). The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol, 171, 2250-4.

Félix J, Andreozzi V, Soares M, et al (2011). Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value in Health, 14, 499-505.

Wendy Max. Dorothy P.Ric. et al. Burden of Prostate Cancer in California 1998:CANCER June 1, 2002 : 94 : 11:2906-2913.

Goh P, Harris K, Napolskikh J, et al (2007). New integrative therapies for oncology: multidisciplinary prostate bone metastases clinic: first of its kind in Canada. Current Oncology, 14, 9-12.

Payne H, Pearcy R (2012). Symptoms and health-related quality of life in castration-resistant prostate cancer: the patient’s perspective. J Men’s Health, 9, 9-16.

David CM, Martin GS, Rodney LD, et al (2005). Long-term outcomes among Localized Prostate Cancer Survivors: Health-Related Quality-of-Life Changes After Radical Prostatectomy, External Radiation, and Brachytherapy. J ClinOncol, 23, 2271-80

Mohamad Rodi I, Moy Foong M, Azad Hassan A.R et al QoL and Associated Factors among Prostate Cancer Patients in in Kuala Lumpur, Malaysia Asian Pacific J Cancer Prev, 13 (12), 5999-6004

Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation,or brachytherapy for early-stage prostate cancer. Cancer 2007;109:2239-47.

Rabow MW, Lee MX. Palliative care in castrate-resistant prostate cancer. Urol Clin North Am 2012;39:491-503.

Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009;302:741-9.

Gade G, Venohr I, Conner D, et al. Impact of an inpatient palliative care team: a randomized control trial. J Palliat Med 2008;11:180-90.

Temel JS, Greer JA, Admane S, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol 2011;29:2319-26

Dalal S, Palla S, Hui D, et al. Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center. Oncologist 2011;16:105-11.

World Health Organization. Report on the Workshop on Strengthening Health Professional Education in Cancer Pain Relief and Development of Palliative Care Expertise, Saitama, Japan. World Health Organization Regional Office for the Western Pacific 1998